Skip to Main Content
Atlanta, GA – June 22, 2023

SENTA Expands Offering with South Carolina ENT, Adding Ambulatory Surgical Center

The only dedicated ENT surgical center in the Columbia, SC market

Today, SENTA (“Southern Ear, Nose, Throat and Allergy Physicians”) proudly announces that South Carolina ENT, Allergy & Sleep Medicine (“SCENT”) is expanding to include a new 21,000 sq. ft. flagship building, housing a fourteen exam room clinic, a six-days-a-week walk-in clinic, and a state-of-the-art ambulatory surgical center (ASC).  This innovative, patient-centered facility will specialize in providing high-quality, compassionate care in an outpatient and ambulatory setting. SENTA Partners is backed by Shore Capital Partners and is committed to partnering with leading physicians to build a premier network of ENT and allergy services in the U.S.    

“SCENT Surgical Center will be the only surgical center in Columbia exclusively specializing in ENT surgical procedures. This center will enable us to provide the very latest in quality care to our patients throughout South Carolina,” said Robert Puchalski, M.D., medical director. “SENTA’s unparalleled support and expertise have allowed us to accelerate our growth in the marketplace; I can’t wait to see the positive impact this new offering will have on physician recruitment, the efficiency of care, savings for our commercially-insured patients, and most importantly, the overall health of our local community.” 

SCENT Ambulatory Surgical Center in South Carolina has a highly trained professional staff committed to providing patients with the best care and treatments possible. It is the second-largest privately-owned ENT and Allergy practice in the state. The surgeons at SCENT Surgical Center are board-certified and specialize in a wide spectrum of ENT surgical procedures. SCENT physicians also partner with the University of South Carolina School of Medicine, providing elective rotations for residents and medical students. SCENT physicians also take a leading role in the medical community by partnering with MUSC and PRISMA to provide consultative on-call services for inpatients and emergency department patients.

“Partnering with our practices to understand and identify what’s needed in their community is key to success both to accelerate our treatment capabilities and grow the business,” said Adam Low, CEO of SENTA.  “Identifying best practices and scaling them, such as the addition of the ASC in the South Carolina market, along with exceptional quality patient care, is a cornerstone for SENTA, and this further delivers on our mission.”  

If interested in learning more about a partnership with SENTA, contact the Chief Development Officer, Zack Usilton, at [email protected] 

About SENTA Partners

Southern Ear, Nose, Throat and Allergy Physicians (SENTA) is a leading community of the finest ENT and Allergy/Immunology specialists in the Southern region. SENTA provides the highest quality allergy, asthma, immunology, and otolaryngology care leading to better patient outcomes. Founded in 2019 with an investment from Shore Capital Partners, SENTA provides strategic, operational, and administrative support to our ENT partner practices and allergy, empowering physicians to focus on their patients. 

About Shore Capital Partners

Shore Capital, a Chicago based private equity firm with offices in Nashville, is an investor in microcap companies in the Healthcare, Food and Beverage, Business Services, and Real Estate industries. Shore’s strategy is to support management partners to grow faster with less risk, through access to capital, world class board and operational resources, and unmatched networking, development, and shared learnings across the portfolio. For the third consecutive year in 2022, Shore received recognition from Inc. Magazine as a top founder friendly investor, and by Pitchbook research for leading all U.S. Private equity firms in total deal volume. Shore targets investments in proven, successful private companies with superior management teams, stable cash flow, and significant potential to grow through industry consolidation and organic growth to generate value for shareholders. Shore has approximately $3 billion of cumulative capital commitments through various investment vehicles. For more information, please visit

Follow us on LinkedIn for company updates